Last reviewed · How we verify
Neurapas balance
Neurapas balance is a Small molecule drug developed by Pascoe Pharmazeutische Praeparate GmbH. It is currently in Phase 1 development.
Neurapas balance is a herbal product containing a combination of Hypericum, Passionflower, and Valerian. It has been studied in clinical trials for conditions such as sleep quality, depressive disorder, nervousness, and restlessness, with its mechanism of action not specified in the available data.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Neurapas balance |
|---|---|
| Sponsor | Pascoe Pharmazeutische Praeparate GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of NEURAPAS Balance in Children With Nervous Restlessness
- Study of the Antidepressant Efficacy of a Combination Herbal Drug Preparation (NEURAPAS Balance) (PHASE3)
- Study to Investigate Effects of a Herbal Drug Compared to Placebo on Sleep (PHASE1)
- Pharmacological Effects of Neurapas® Balance and Pascoflair® 425 mg on Brain Activity in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neurapas balance CI brief — competitive landscape report
- Neurapas balance updates RSS · CI watch RSS
- Pascoe Pharmazeutische Praeparate GmbH portfolio CI
Frequently asked questions about Neurapas balance
What is Neurapas balance?
Who makes Neurapas balance?
What development phase is Neurapas balance in?
Related
- Manufacturer: Pascoe Pharmazeutische Praeparate GmbH — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing